A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Active, not recruiting · Phase 2 · NCT06643728
Conditions: Obesity, Overweight
At a glance
- Research payments reported, 2025
- $15.5M
- U.S. investigators named
- 14
- Sites paid
- 17
- Planned or actual enrollment
- 252
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Bimagrumab (drug), Tirzepatide (drug), Bimagrumab Placebo (drug), Tirzepatide Placebo (drug)
- Dates
- Started 2024-10-21; completion 2027-01
- Results posted
- Not yet
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
From ClinicalTrials.gov, last updated 2026-05-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $15.5M in research payments for this study in 2025 (32 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David D. Deatkine, MD Internal Medicine · Birmingham, AL
- Almena Free, M.D. Internal Medicine · Anniston, AL
- Bonnie S. Kimmel, M.D. Endocrinology & Diabetes · Walnut Creek, CA
- John M. Joyce, M. D. Psychiatry · Jacksonville, FL
- Samuel N. Lederman, M.D. OB-GYN (Obstetrics & Gynecology) · Lake Worth, FL
- Cindy H. Pau, MD Endocrinology & Diabetes · Honolulu, HI
- Khaleel Sayeed, M.D. Nephrology (Kidney) · Chicago, IL
- Michael J. Hafran, M.D. Family Medicine · East Lansing, MI
- Bob Hutchins Internal Medicine · Jackson, MS
- Bliss J. Chang, MD Cardiology · Albany, NY
- Cameron S. Olezene, MD Physical Medicine & Rehabilitation (PM&R) · Philadelphia, PA
- Felix O. Berglund, MD Cardiology · Nashville, TN
- Frances E. Broyles, MD Endocrinology & Diabetes · Seattle, WA
- Javier Nazar, MD General Practice · Redmond, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Flourish Research Acquisition LLC $5.8M
- Clinitiative LLC DBA Clinitiative Health Research $2.1M
- Eastside Research Associates LLC $2.0M
- David Fitzpatrick MD DBA E West Med Rsrch $1.7M
- Rainier Clinical Research Center Inc $1.5M
- Clinical Neuroscience Solutions DBA Cns Hlthcare $1.1M
- Pinnacle Research Group LLC $808,390
- Sky Clinical Research Network Group $295,363
- Great Lakes Clinical Trials $28,113
- $26,788
- Suncoast Research $24,115
- Central Research Associates, Inc $13,185
- Keystone Clin Studies $12,152
- Rainier Clinical Research Center $10,392
- Sociedad Espanola De Medicina De La Adolescencia $10,382
- Clinical Trials of Texas Inc $175
- Cleveland Clinic, OH $99
- Pinnacle Clinical Research LLC $9
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.